CHAMPIONS ONCOLOGY, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
CHAMPIONS ONCOLOGY, INC. (CSBR) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $766.00 thousand for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-11.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-09-11
- CHAMPIONS ONCOLOGY, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-07-31 was $766.00K, a 268.27% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-01-31 was $423.00K, a 65.23% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-10-31 was $249.00K, a 2666.67% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-07-31 was $208.00K, a 19.38% decline year-over-year.
- CHAMPIONS ONCOLOGY, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2026 was $1.24M, a 89.14% increase from fiscal 2025.
- CHAMPIONS ONCOLOGY, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $654.00K, a 41.50% decline from fiscal 2024.
- CHAMPIONS ONCOLOGY, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.12M, a 29.40% increase from fiscal 2023.
- CHAMPIONS ONCOLOGY, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $864.00K, a 5.26% decline from fiscal 2022.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-07-31 | $766.00K 10-Q · filed 2026-09-11 | ||||
| 2026-04-30 | $1.24M 10-K · filed 2026-07-27 | ||||
| 2026-01-31 | $423.00K 10-Q · filed 2026-03-12 | $672.00K derived: sum of 2 quarters · filed 2026-03-12 | $880.00K derived: sum of 3 quarters · filed 2026-09-11 | ||
| 2025-10-31 | $249.00K 10-Q · filed 2026-03-12 | $457.00K derived: sum of 2 quarters · filed 2026-09-11 | |||
| 2025-07-31 | $208.00K 10-Q · filed 2026-09-11 | ||||
| 2025-04-30 | $654.00K 10-K · filed 2026-07-27 | ||||
| 2025-01-31 | $256.00K 10-Q · filed 2026-03-12 | $265.00K derived: sum of 2 quarters · filed 2026-03-12 | $523.00K derived: sum of 3 quarters · filed 2026-03-12 | ||
| 2024-10-31 | $9.00K 10-Q · filed 2026-03-12 | $267.00K derived: sum of 2 quarters · filed 2026-03-12 | |||
| 2024-07-31 | $258.00K 10-Q · filed 2026-03-12 | ||||
| 2024-04-30 | $1.12M 10-K · filed 2025-07-23 | ||||
| 2024-01-31 | $379.00K 10-Q · filed 2025-03-17 | $432.00K derived: sum of 2 quarters · filed 2025-03-17 | $855.00K derived: sum of 3 quarters · filed 2025-03-17 | ||
| 2023-10-31 | $53.00K 10-Q · filed 2025-03-17 | $476.00K derived: sum of 2 quarters · filed 2025-03-17 | |||
| 2023-07-31 | $423.00K 10-Q · filed 2025-03-17 | ||||
| 2023-04-30 | $864.00K 10-K · filed 2024-07-19 | ||||
| 2023-01-31 | $331.00K 10-Q · filed 2024-03-15 | $450.00K derived: sum of 2 quarters · filed 2024-03-15 | $656.00K derived: sum of 3 quarters · filed 2024-03-15 | ||
| 2022-10-31 | $119.00K 10-Q · filed 2024-03-15 | $325.00K derived: sum of 2 quarters · filed 2024-03-15 | |||
| 2022-07-31 | $206.00K 10-Q · filed 2024-03-15 | ||||
| 2022-04-30 | $912.00K 10-K · filed 2023-07-24 | ||||
| 2022-01-31 | $310.00K 10-Q · filed 2023-03-16 | $444.00K derived: sum of 2 quarters · filed 2023-03-16 | $724.00K derived: sum of 3 quarters · filed 2023-03-16 | ||
| 2021-10-31 | $134.00K 10-Q · filed 2023-03-16 | $414.00K derived: sum of 2 quarters · filed 2023-03-16 | |||
| 2021-07-31 | $280.00K 10-Q · filed 2023-03-16 | ||||
| 2021-04-30 | $598.00K 10-K · filed 2022-07-22 | ||||
| 2021-01-31 | $232.00K 10-Q · filed 2022-03-15 | $317.00K derived: sum of 2 quarters · filed 2022-03-15 | $437.00K derived: sum of 3 quarters · filed 2022-03-15 | ||
| 2020-10-31 | $85.00K 10-Q · filed 2022-03-15 | $205.00K derived: sum of 2 quarters · filed 2022-03-15 | |||
| 2020-07-31 | $120.00K 10-Q · filed 2022-03-15 | ||||
| 2020-04-30 | $600.00K 10-K · filed 2021-07-26 | ||||
| 2020-01-31 | $120.00K 10-Q · filed 2021-09-13 | $229.00K 10-Q · filed 2020-03-16 | $197.00K derived: sum of 2 quarters · filed 2021-09-13 | $328.00K derived: sum of 3 quarters · filed 2021-09-13 | |
| 2019-10-31 | $77.00K 10-Q · filed 2021-03-15 | $208.00K derived: sum of 2 quarters · filed 2021-03-15 | |||
| 2019-07-31 | $131.00K 10-Q · filed 2021-03-15 | ||||
| 2019-04-30 | $636.00K 10-K · filed 2020-07-28 | ||||
| 2019-01-31 | $335.00K 10-Q · filed 2020-03-16 | $423.00K derived: sum of 2 quarters · filed 2020-03-16 | $498.00K derived: sum of 3 quarters · filed 2020-03-16 | ||
| 2018-10-31 | $88.00K 10-Q · filed 2020-03-16 | $163.00K derived: sum of 2 quarters · filed 2020-03-16 | |||
| 2018-07-31 | $75.00K 10-Q · filed 2020-03-16 | ||||
| 2018-04-30 | $1.00M 10-K · filed 2019-07-29 | ||||
| 2017-04-30 | $2.66M 10-K · filed 2018-07-30 | ||||
| 2016-04-30 | $2.60M 10-K · filed 2017-07-28 | ||||
| 2015-04-30 | $2.95M 10-K · filed 2016-07-29 | ||||
| 2014-04-30 | $2.81M 10-K · filed 2015-07-29 | ||||
| 2013-04-30 | $2.38M 10-K · filed 2014-07-28 | ||||
| 2012-04-30 | $3.32M 10-K · filed 2013-07-26 | ||||
| 2011-04-30 | $3.13M 10-K · filed 2012-07-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |